================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended Commission file number 1-1225
June 30, 2002
Wyeth
-----
(Exact name of registrant as specified in its charter)
Delaware 13-2526821
-------- ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
Five Giralda Farms, Madison, N.J. 07940
--------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (973) 660-5000
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d)
of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
Yes X No
------ --
The number of shares of Common Stock outstanding as of the close of business
on July 31, 2002:
Number of
Class Shares Outstanding
----- ------------------
Common Stock, $0.33-1/3 par value 1,325,128,566
================================================================================
WYETH AND SUBSIDIARIES
INDEX
Page No.
--------
Part I - Financial Information 2
Item 1. Consolidated Condensed Financial Statements:
Consolidated Condensed Balance Sheets -
June 30, 2002 and December 31, 2001 3
Consolidated Condensed Statements of Operations -
Three and Six Months Ended June 30, 2002 and 2001 4
Consolidated Condensed Statements of Changes in
Stockholders' Equity - Six Months Ended June 30,
2002 and 2001 5
Consolidated Condensed Statements of Cash Flows -
Six Months Ended June 30, 2002 and 2001 6
Notes to Consolidated Condensed Financial Statements 7-14
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 15-25
Part II - Other Information 26
Item 1. Legal Proceedings 26-28
Item 4. Submission of Matters to a Vote of Security-Holders 29
Item 6. Exhibits and Reports on Form 8-K 30-31
Signature 32
Exhibit Index EX-1
Items other than those listed above have been omitted because they are not
applicable.
1
Part I - Financial Information
------------------------------
WYETH AND SUBSIDIARIES
The consolidated condensed financial statements included herein have been
prepared by Wyeth (the "Company"), without audit, pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States
have been condensed or omitted pursuant to such rules and regulations; however,
the Company believes that the disclosures are adequate to make the information
presented not misleading. In the opinion of management, the consolidated
condensed financial statements include all adjustments necessary to present
fairly the financial position of the Company as of June 30, 2002 and December
31, 2001, the results of operations for the three months and six months ended
June 30, 2002 and 2001 and changes in stockholders' equity and cash flows for
the six months ended June 30, 2002 and 2001. It is suggested that these
consolidated condensed financial statements and management's discussion and
analysis of financial condition and results of operations be read in conjunction
with the financial statements and the notes thereto included in the Company's
2001 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the
quarter ended March 31, 2002.
As of January 1, 2002, the Company adopted new authoritative accounting guidance
reflecting certain vendor allowances (i.e., cooperative advertising
arrangements) as reductions of revenues instead of selling and marketing
expenses. Financial information for all prior periods presented has been
reclassified to comply with the income statement classification requirements of
the new guidance.
As of January 1, 2002, the Company also adopted SFAS No. 142, Goodwill and
Other Intangible Assets and SFAS No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets. SFAS No. 144 did not have any impact on
the Company during the 2002 first half. Refer to Note 1 of the
Consolidated Condensed Financial Statements for disclosure relating to the
implementation of SFAS No. 142.
2
WYETH AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(In Thousands Except Per Share Amounts)
(Unaudited)
June 30, December 31,
2002 2001
----------- ------------
ASSETS
Cash and cash equivalents $1,644,874 $1,744,734
Marketable securities 1,531,350 1,281,988
Accounts receivable less allowances 2,831,696 2,743,040
Inventories:
Finished goods 765,966 653,108
Work in progress 864,592 674,636
Materials and supplies 448,226 427,227
----------- ------------
2,078,784 1,754,971
Other current assets including deferred taxes 1,877,894 2,242,020
----------- ------------
Total Current Assets 9,964,598 9,766,753
Property, plant and equipment 9,333,798 8,944,451
Less accumulated depreciation 2,886,946 2,662,291
----------- ------------
6,446,852 6,282,160
Goodwill 3,752,454 3,725,547
Other intangibles, net of accumulated amortization
(June 30, 2002-$82,880 and December 31, 2001-$71,070) 120,393 126,387
Other assets including deferred taxes 3,843,790 3,067,075
----------- ------------
Total Assets $24,128,087 $22,967,922
=========== ============
LIABILITIES
Loans payable $3,405,839 $2,097,354
Trade accounts payable 583,246 672,457
Dividends payable 304,732 -
Accrued expenses 3,356,135 4,257,523
Accrued federal and foreign taxes 68,148 229,847
----------- ------------
Total Current Liabilities 7,718,100 7,257,181
Long-term debt 7,427,719 7,357,277
Accrued postretirement benefit obligations other than pensions 948,707 925,098
Other noncurrent liabilities 3,195,080 3,355,793
STOCKHOLDERS' EQUITY
$2.00 convertible preferred stock, par value $2.50 per share 47 51
Common stock, par value $0.33-1/3 per share 441,614 440,190
Additional paid-in capital 4,494,114 4,295,051
Retained earnings 616,949 170,309
Accumulated other comprehensive loss (714,243) (833,028)
----------- ------------
Total Stockholders' Equity 4,838,481 4,072,573
----------- ------------
Total Liabilities and Stockholders' Equity $24,128,087 $22,967,922
=========== ============
The accompanying notes are an integral part of these consolidated condensed financial statements.
3
WYETH AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(In Thousands Except Per Share Amounts)
(Unaudited)
Three Months Six Months
Ended June 30, Ended June 30,
------------------------ ------------------------
2002 2001 2002 2001
---------- ---------- ---------- ----------
Net Revenue $3,502,848 $3,183,393 $7,146,369 $6,600,677
---------- ---------- ---------- ----------
Cost of goods sold 887,215 791,041 1,689,394 1,589,644
Selling, general and administrative expenses 1,310,100 1,258,428 2,580,384 2,512,004
Research and development expenses 526,867 477,533 1,007,073 928,522
Interest expense, net 55,621 49,554 108,959 53,493
Other income, net (48,690) (25,053) (133,338) (95,864)
---------- ---------- ---------- ----------
Income before federal and foreign taxes 771,735 631,890 1,893,897 1,612,878
Provision for federal and foreign taxes 171,876 154,894 422,118 402,328
---------- ---------- ---------- ----------
Net Income $599,859 $476,996 $1,471,779 $1,210,550
========== ========== ========== ==========
Basic earnings per share $0.45 $0.36 $1.11 $0.92
========== ========== ========== ==========
Diluted earnings per share $0.45 $0.36 $1.10 $0.91
========== ========== ========== ==========
Dividends paid per share of common stock $0.23 $0.23 $0.46 $0.46
========== ========== ========== ==========
Dividends declared per share of common stock $0.46 $0.46 $0.69 $0.69
========== ========== ========== ==========
The accompanying notes are an integral part of these consolidated condensed financial statements.
4
WYETH AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In Thousands Except Per Share Amounts)
(Unaudited)
Six Months Ended June 30, 2002:
$2.00 Accumulated
Convertible Additional Other Total
Preferred Common Paid-in Retained Comprehensive Stockholders'
Stock Stock Capital Earnings Loss Equity
----------- -------- ---------- ---------- ------------- -------------
Balance at January 1, 2002 $51 $440,190 $4,295,051 $170,309 ($833,028) $4,072,573
Net income 1,471,779 1,471,779
Currency translation adjustments 152,093 152,093
Unrealized losses on derivative
contracts (25,764) (25,764)
Unrealized losses on marketable
securities (7,544) (7,544)
------------
Comprehensive income 1,590,564
------------
Cash dividends declared (1) (914,172) (914,172)
Purchases of common stock for treasury (667) (5,472) (107,788) (113,927)
Common stock issued for stock options 1,956 184,773 186,729
Other exchanges (4) 135 19,762 (3,179) 16,714
----------- -------- ---------- ---------- ------------- ------------
Balance at June 30, 2002 $47 $441,614 $4,494,114 $616,949 ($714,243) $4,838,481
=========== ======== ========== ========== ============= ============
Six Months Ended June 30, 2001:
$2.00 Accumulated
Convertible Additional Other Total
Preferred Common Paid-in Accumulated Comprehensive Stockholders'
Stock Stock Capital Deficit Loss Equity
----------- -------- ---------- ----------- ------------- -------------
Balance at January 1, 2001 $55 $437,258 $3,952,457 ($899,118) ($672,559) $2,818,093
Net income 1,210,550 1,210,550
Currency translation adjustments (155,729) (155,729)
Unrealized gains on derivative
contracts 16,135 16,135
Unrealized gains on marketable
securities 1,878 1,878
------------
Comprehensive income 1,072,834
------------
Cash dividends declared (2) (907,287) (907,287)
Common stock issued for stock options 1,548 127,337 128,885
Other exchanges (2) 102 12,514 (2,724) 9,890
----------- -------- ---------- ---------- ------------- ------------
Balance at June 30, 2001 $53 $438,908 $4,092,308 ($598,579) ($810,275) $3,122,415
=========== ======== ========== ========== ============= ============
(1) Includes the 2002 third quarter common stock cash dividend of $0.23 per share ($304,713 in the aggregate) declared on
June 20, 2002 and payable on September 1, 2002, and the 2002 second and third quarter preferred stock cash dividends
of $0.50 per share ($19 in the aggregate) paid on July 1, 2002 and payable on October 1, 2002, respectively.
(2) Includes the 2001 third quarter common stock cash dividend of $0.23 per share ($302,847 in the aggregate) declared on
June 21, 2001 and paid on September 1, 2001, and the 2001 second and third quarter preferred stock cash dividends of
$0.50 per share ($21 in the aggregate) paid on July 1, 2001 and October 1, 2001, respectively.
The accompanying notes are an integral part of these consolidated condensed financial statements.
5
WYETH AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(In Thousands)
(Unaudited)
Six Months
Ended June 30,
2002 2001
---------- ----------
Operating Activities
- --------------------
Net income $1,471,779 $1,210,550
Adjustments to reconcile net income to net cash
used for operating activities:
Gains on sales of assets (105,908) (102,577)
Depreciation and amortization 242,131 294,924
Deferred income taxes 69,071 163,360
Changes in working capital, net (372,503) 55,314
Diet drug litigation payments (895,919) (5,948,929)
Security fund deposit (415,000) -
Other items, net (314,070) (52,058)
---------- ----------
Net cash used for operating activities (320,419) (4,379,416)
---------- ----------
Investing Activities
- --------------------
Purchases of property, plant and equipment (787,684) (843,225)
Proceeds from sales of assets 412,132 253,350
Proceeds from sales and maturities of marketable securities 1,294,609 114,298
Purchases of marketable securities (1,543,971) (529,147)
---------- ----------
Net cash used for investing activities (624,914) (1,004,724)
---------- ----------
Financing Activities
- --------------------
Net proceeds from debt 1,377,224 5,626,438
Dividends paid (609,440) (604,419)
Purchases of common stock for treasury (113,927) -
Exercises of stock options 186,729 128,885
---------- ----------
Net cash provided from financing activities 840,586 5,150,904
---------- ----------
Effects of exchange rates on cash balances 4,887 (17,721)
---------- ----------
Decrease in cash and cash equivalents (99,860) (250,957)
Cash and cash equivalents, beginning of period 1,744,734 2,644,306
---------- ----------
Cash and cash equivalents, end of period $1,644,874 $2,393,349
========== ==========
Supplemental Information
- ------------------------
Interest payments $183,612 $120,469
Income tax payments, net of refunds 295,239 241,287
The accompanying notes are an integral part of these consolidated condensed financial statements.
6
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Goodwill and Other Intangibles
------------------------------
Transitional Disclosure:
On January 1, 2002, the Company adopted SFAS No. 142, Goodwill and
Other Intangible Assets. With the adoption of SFAS No. 142, goodwill
and other intangibles with indefinite lives are no longer being
amortized but are subject to at least an annual assessment for
impairment by applying a fair-value based test. Other intangibles with
finite lives continue to be amortized.
SFAS No. 142 requires that goodwill be tested for impairment at the
reporting unit level at adoption utilizing a two step methodology. The
initial step requires the Company to determine the fair value of each
reporting unit and compare it to the carrying value, including
goodwill, of such unit. If the fair value exceeds the carrying value,
no impairment loss would be recognized. However, if the carrying value
of the reporting unit exceeds its fair value, the goodwill of the
reporting unit may be impaired. The amount, if any, of the impairment
would then be measured in the second step.
In connection with adopting the standard as of January 1, 2002, the
Company completed step one of the test for impairment during the 2002
second quarter and determined that there was no impairment of the
recorded goodwill.
The Company's other intangibles, which all have finite lives, have
carrying values of $120.4 million and $126.4 million at June 30, 2002
and December 31, 2001, respectively and are being amortized over their
estimated useful lives ranging from three to 10 years.
The following table presents net income and basic and diluted earnings
per share for the three and six months ended June 30, 2002 and 2001 to
reflect the adoption of SFAS No. 142 as of January 1, 2002.
Three Months Six Months
Ended June 30, Ended June 30,
-------------------- ------------------------
(In thousands, except per share amounts) 2002 2001 2002 2001
---------------------------------------- -------- -------- ---------- ----------
As-reported net income $599,859 $476,996 $1,471,779 $1,210,550
Add back: goodwill amortization - 38,220 - 76,933
-------- -------- ---------- ----------
Adjusted net income $599,859 $515,216 $1,471,779 $1,287,483
======== ======== ========== ==========
Basic earnings per share:
As-reported $0.45 $0.36 $1.11 $0.92
Goodwill amortization - 0.03 - 0.06
-------- -------- ---------- ----------
Adjusted $0.45 $0.39 $1.11 $0.98
======== ======== ========== ==========
Diluted earnings per share:
As-reported $0.45 $0.36 $1.10 $0.91
Goodwill amortization - 0.03 - 0.06
-------- -------- ---------- ----------
Adjusted $0.45 $0.39 $1.10 $0.97
======== ======== ========== ==========
7
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Goodwill:
The changes in the carrying amount of goodwill by segment for the six
months ended June 30, 2002, are as follows:
Consumer
(In thousands) Pharmaceuticals Healthcare Total
-------------------------------- --------------- ---------- ----------
Balance at January 1, 2002 $3,136,543 $589,004 $3,725,547
Currency translation adjustments 26,041 866 26,907
---------- -------- ----------
Balance as of June 30, 2002 $3,162,584 $589,870 $3,752,454
========== ======== ==========
Note 2. Credit Facilities
-----------------
At June 30, 2002, the Company had commercial paper outstanding of
$6,138.4 million. The commercial paper outstanding was supported by
$4,000.0 million of credit facilities, as follows:
o In March 2002, the Company renewed its $3,000.0 million credit
facility for an additional 364-day term. Any borrowings under the
$3,000.0 million, 364-day credit facility that are outstanding
upon its termination in March 2003 are extendible by the Company
for an additional year. The portion of commercial paper
outstanding at June 30, 2002 supported by the $3,000.0 million,
364-day credit facility was classified as Long-term debt since
the Company intends, and has the ability, to refinance these
obligations through the issuance of additional commercial paper
or through the use of its $3,000.0 million credit facility.
o Also in March 2002, the Company reduced the $2,000.0 million
credit facility to $1,000.0 million, which terminated on July 31,
2002. Since the $1,000.0 million credit facility terminated on
July 31, 2002, commercial paper outstanding of $1,000.0 million,
supported by this facility, was classified as current debt in
Loans payable at June 30, 2002.
The remaining balance of $2,138.4 million (which is classified as
current debt in Loans payable because it is not supported by the
credit facilities) is supported by $3,176.2 million of cash and cash
equivalents and marketable securities.
On August 8, 2002, following the termination of the Company's $1,000.0
million credit facility, the Company obtained a 364-day $2,000.0
million credit facility, which contemplates a potential increase to
$3,000.0 million if the Company so requests and lenders agree to
participate. The facility will be reduced to 66.67% of its committed
amount on December 31, 2002 and to 33.34% of its committed amount on
May 8, 2003. In addition, in the event the Company enters into certain
alternative financings or asset sales, the committed amount will be
reduced by the amount of proceeds received therefrom.
8
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Note 3. Contingencies and Litigation Settlement
---------------------------------------
The Company is involved in various legal proceedings, including
product liability and environmental matters of a nature considered
normal to its business. It is the Company's policy to accrue for
amounts related to these legal matters if it is probable that a
liability has been incurred and an amount is reasonably estimable.
On July 9, 2002, findings from the Women's Health Initiative (WHI)
study evaluating hormone replacement therapy were released and the
subset of the study involving use of the Company's PREMPRO product was
stopped early. This subset was stopped early because, according to the
predefined stopping rule, the increased risk of breast cancer and
cardiovascular events exceeded the specified long-term benefits. Since
that announcement, the Company has been named in six putative class
action lawsuits. Four of the six putative class actions seek to
represent a nationwide class of all women who have ever purchased or
ingested PREMPRO and seek, on behalf of the class, purchase price
refunds, personal injury damage, medical monitoring expenses and an
order requiring the Company to inform the public of the reported risks
of PREMPRO. The other two putative class actions each seek to
represent a class of Pennsylvania women who have ingested the drug and
seek purchase price refunds and medical monitoring expenses on behalf
of the class. The Company expects that additional PREMPRO cases may be
filed in the future. At this time, the Company is unable to determine
any possible range of loss relating to the PREMPRO litigation and has
not established any reserve with respect to any such litigation, but
expects to incur costs in connection with the defense of the PREMPRO
litigation. The Company believes it has meritorious defenses against
these claims and intends to vigorously defend any PREMPRO litigation.
The nationwide class action settlement to resolve litigation brought
against the Company regarding use of the diet drugs REDUX or PONDIMIN
received final judicial approval effective January 3, 2002. The
Company recorded an initial litigation charge of $4,750.0 million, net
of insurance, in connection with the REDUX and PONDIMIN litigation in
1999, an additional charge of $7,500.0 million in 2000, and a third
litigation charge of $950.0 million in the 2001 third quarter. These
charges are intended to cover the total amount required to resolve all
diet drug litigation, including anticipated funding requirements for
the nationwide, class action settlement, anticipated costs to resolve
the claims of any members of the settlement class who in the future
may exercise an intermediate or back-end opt out right, costs to
resolve the claims of PPH claimants and initial opt out claimants, and
administrative and litigation expenses.
During the 2002 first half, payments to the nationwide, class action
settlement funds, individual settlement payments, legal fees and other
costs totaling $895.9 million were paid and applied against the
litigation accrual. As of June 30, 2002, $961.8 million of the
litigation accrual remained.
On January 18, 2002, as collateral for the Company's financial
obligations under the settlement, the Company established a security
fund in the amount of $370.0 million and recorded such amount in Other
assets including deferred taxes. In April 2002, pursuant to an
agreement among the Company, class counsel and representatives of the
settlement
9
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
trust, an additional $45.0 million, also included in Other assets
including deferred taxes, was added to the security fund, bringing the
total amount in the security fund to $415.0 million. The funds are
owned by the Company and will earn interest income for the Company
while residing in the security fund. The Company will be required to
deposit an additional $180.0 million in the security fund if the
Company's credit rating, as reported by both Moody's and Standard &
Poor's (S&P), falls below investment grade.
Under the terms of the nationwide class action settlement, the period
during which class members could register to receive a screening
echocardiogram from the settlement trust ended on August 1, 2002.
Those echocardiograms, as well as echocardiograms that class members
choose to receive on their own outside the settlement, must be
completed by January 3, 2003, unless that date is extended by the
court. Class members whose echocardiograms demonstrate FDA-positive
levels of heart valve regurgitation (mild or greater aortic valve
regurgitation or moderate or greater mitral valve regurgitation) must
elect either to remain in the settlement or to withdraw from the
settlement and proceed as an intermediate opt-out (with specific
rights and limitations defined in the settlement) by May 3, 2003.
Based upon the information available at this time, the Company
believes that the balance remaining in its reserves will be adequate
to cover the remaining obligations relating to the diet drug
litigation. However, in light of the inherent uncertainty in
estimating litigation exposure and the fact that substantial
additional information will become available in the coming months, it
is possible that additional reserves will be required.
In the opinion of the Company, although the outcome of any legal
proceedings cannot be predicted with certainty, the ultimate liability
of the Company in connection with its legal proceedings will not have
a material adverse effect on the Company's financial position but
could be material to the results of operations or cash flows in any
one accounting period.
Note 4. Restructuring Programs
----------------------
In December 1998, the Company recorded a special charge for
restructuring and related asset impairments of $321.2 million to
recognize costs of the reorganization of its worldwide supply chains
and U.S. distribution systems, and the globalization of certain
business units. The restructuring will ultimately result in the
elimination of approximately 3,900 positions worldwide offset, in
part, by 1,000 newly created positions in the same functions at other
locations. At June 30, 2002, approximately 3,830 positions had been
eliminated, and two distribution centers owned by the Company and a
leased distribution center had been closed. The Company anticipates
closing a total of 14 manufacturing plants, of which eight were closed
in 2000 and two were closed during 2001. The Company currently
anticipates utilizing most of the remainder of the restructuring
accruals in 2002, assuming no further delays in regulatory approval.
10
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
The activity in the restructuring accruals was as follows:
Personnel Other Closure/
(In thousands) Costs Exit Costs Total
------------------------------------------- --------- -------------- -------
Restructuring accruals at December 31, 2001 $9,037 $30,619 $39,656
Cash expenditures (948) (5,002) (5,950)
------ ------- -------
Restructuring accruals at June 30, 2002 $8,089 $25,617 $33,706
====== ======= =======
Note 5. Company Data by Operating Segment
---------------------------------
The Company has three reportable segments: Pharmaceuticals, Consumer
Healthcare and Corporate. The Company's Pharmaceuticals and Consumer
Healthcare reportable segments are strategic business units that are
managed separately because they manufacture, distribute and sell
distinct products and provide services, which require various
technologies and marketing strategies.
Net Revenue (1)
--------------------------------------------
Three Months Six Months
Ended June 30, Ended June 30,
($ in millions) -------------------- --------------------
Operating Segment 2002 2001 2002 2001
----------------------- -------- -------- -------- --------
Pharmaceuticals $3,009.7 $2,694.0 $6,158.8 $5,573.3
Consumer Healthcare 493.1 489.4 987.6 1,027.4
-------- -------- -------- --------
Total $3,502.8 $3,183.4 $7,146.4 $6,600.7
======== ======== ======== ========
Income Before Taxes (2)
--------------------------------------------
Three Months Six Months
Ended June 30, Ended June 30,
($ in millions) -------------------- --------------------
Operating Segment 2002 2001 2002 2001
----------------------- -------- -------- -------- --------
Pharmaceuticals $736.6 $601.2 $1,809.8 $1,516.7
Consumer Healthcare (3) 143.4 112.1 302.9 236.1
------ ------ -------- --------
880.0 713.3 2,112.7 1,752.8
Corporate (108.3) (81.4) (218.8) (139.9)
------ ------ -------- --------
Total $771.7 $631.9 $1,893.9 $1,612.9
====== ====== ======== ========
(1) The Company adopted new authoritative accounting guidance as of
January 1, 2002 reflecting the cost of certain vendor
considerations (i.e., cooperative advertising payments) as
reductions of revenue instead of selling and marketing expenses.
Financial information for all prior periods presented has been
reclassified to comply with the income statement classification
requirements of the new guidance. These reclassifications had no
effect on total net revenue growth between the periods presented.
(2) In accordance with new authoritative accounting guidance, adopted
as of January 1, 2002, the Company has ceased amortizing
goodwill. The 2001 second quarter goodwill amortization was as
11
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
follows: Pharmaceuticals - $34.1 and Consumer Healthcare - $5.9.
The 2001 first half goodwill amortization was as follows:
Pharmaceuticals - $68.7 and Consumer Healthcare - $11.9.
(3) Consumer Healthcare includes gains of $40.3 and $73.9 in the 2002
second quarter and first half, respectively, related to a class
action settlement regarding price fixing by certain vitamin
suppliers.
Note 6. Earnings per Share
------------------
The following table sets forth the computations of basic earnings per
share and diluted earnings per share:
Three Months Six Months
Ended June 30, Ended June 30,
---------------------- ------------------------
(In thousands except per share amounts) 2002 2001 2002 2001
--------------------------------------- --------- --------- ---------- ----------
Net income less preferred dividends $599,840 $476,975 $1,471,750 $1,210,518
Denominator:
Average number of common shares
outstanding 1,325,989 1,316,008 1,324,970 1,314,938
--------- --------- ---------- ----------
Basic earnings per share $0.45 $0.36 $1.11 $0.92
========= ========= ========== ==========
Net income $599,859 $476,996 $1,471,779 $1,210,550
Denominator:
Average number of common shares
outstanding 1,325,989 1,316,008 1,324,970 1,314,938
Common stock equivalents of
outstanding stock options and
deferred common stock awards 10,307 14,649 12,437 14,423
--------- --------- ---------- ----------
Total shares 1,336,296 1,330,657 1,337,407 1,329,361
--------- --------- ---------- ----------
Diluted earnings per share $0.45 $0.36 $1.10 $0.91
========= ========= ========== ==========
Note 7. Sale of Rhode Island Facility
-----------------------------
During the first quarter of 2002, Wyeth completed the sale of a
manufacturing plant located in West Greenwich, Rhode Island, to
Immunex Corporation (subsequently acquired by Amgen Inc.) for $487.8
million. The Company received $189.2 million of these proceeds in 2001
and the remaining $298.6 million during the 2002 first quarter. The
Company did not recognize a gain on this transaction because the
facility was sold at net book value. The facility will be dedicated to
expand the production capacity of ENBREL.
12
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Note 8. Acquisition of Immunex by Amgen
-------------------------------
Prior to July 15, 2002, the Company was the beneficial owner of
223,378,088 shares of common stock of Immunex Corporation (Immunex).
On July 15, 2002, Amgen Inc. (Amgen) completed its acquisition of
Immunex. Under the terms of the acquisition, each share of Immunex
common stock was exchanged for 0.44 shares of Amgen common stock and
$4.50 in cash. Accordingly, the Company received 98,286,359 shares of
Amgen common stock, representing approximately 7.7% of Amgen's
outstanding common stock, and $1,005.0 million in cash in exchange for
all of its shares of Immunex common stock.
Pursuant to the terms of the acquisition, the Company and Amgen agreed
to certain standstill, voting, lock-up and sale volume limitation
provisions with respect to the Amgen common stock received by the
Company. Included in these limitations is a 90-day lock-up period from
the closing date of the transaction (July 15, 2002) where the Company
is prohibited from disposing of its Amgen investment. Subsequent to
the 90-day lock-up, the Company is prohibited, with certain
exceptions, from disposing of greater than an aggregate of 20,000,000
shares of Amgen common stock in any calendar quarter.
The Company and Amgen will continue to co-promote ENBREL in the United
States and Canada with the Company having exclusive international
rights to ENBREL. The financial aspects of the existing licensing and
marketing rights to ENBREL remain unchanged.
Note 9. Pending Sale of Lederle Generic Injectable Business
---------------------------------------------------
A definitive agreement has been signed with Baxter Healthcare
Corporation for the sale of certain assets related to the Company's
generic human injectable pharmaceuticals business. Under the terms of
the agreement, which is subject to customary conditions to closing,
including certain regulatory approvals, the Company will receive
approximately $305.0 million in cash at closing.
Note 10. Summary of Significant Accounting Policies
------------------------------------------
The following policies are in addition to those disclosed in Footnote
1 of the 2001 Annual Report on Form 10-K:
Property, Plant and Equipment is carried at cost. Depreciation is
provided over the estimated useful lives of the related assets,
principally on the straight-line method, as follows:
Buildings 10 - 50 years
Machinery and Equipment 3 - 20 years
13
WYETH AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)
Research and Development Expenses are expensed as incurred. Upfront
and milestone payments made to third parties in connection with
research and development collaborations are expensed as incurred up to
the point of regulatory approval. Payments made to third parties
subsequent to regulatory approval are capitalized and amortized over
the remaining useful life. Amounts capitalized for such payments are
included in Other intangibles, net of accumulated amortization.
14
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
Results of Operations
- ---------------------
The Company adopted new authoritative accounting guidance as of January 1, 2002
reflecting the cost of certain vendor considerations (i.e., cooperative
advertising payments) as reductions of revenue instead of selling and marketing
expenses. Financial information for the prior period presented has been
reclassified to comply with the income statement classification requirements of
the new guidance. These reclassifications had no effect on total net revenue
growth between the periods presented.
Worldwide net revenue for the 2002 second quarter and first half was 10% and 8%
higher, respectively, compared with prior period levels. The increase in
worldwide net revenue for the 2002 second quarter and first half was due
primarily to higher worldwide net revenue of human pharmaceuticals. There was no
foreign exchange impact on worldwide net revenue for the 2002 second quarter,
however, excluding the negative impact of foreign exchange for the 2002 first
half, worldwide net revenue increased 9%.
The following table sets forth worldwide net revenue results by operating
segment together with the percentage changes from the comparable period in the
prior year:
Net Revenue
-----------------------
Three Months
Ended June 30,
($ in millions) -----------------------
Operating Segment 2002 2001 % Increase
- ------------------- -------- -------- ----------
Pharmaceuticals $3,009.7 $2,694.0 12%
Consumer Healthcare 493.1 489.4 1%
-------- -------- ----------
Total $3,502.8 $3,183.4 10%
======== ======== ==========
Net Revenue
-----------------------
Six Months
Ended June 30,
($ in millions) ----------------------- % Increase
Operating Segment 2002 2001 (Decrease)
- ------------------- -------- -------- ----------
Pharmaceuticals $6,158.8 $5,573.3 11%
Consumer Healthcare 987.6 1,027.4 (4)%
-------- -------- ----------
Total $7,146.4 $6,600.7 8%
======== ======== ==========
Pharmaceuticals
- ---------------
Worldwide pharmaceutical net revenue increased 12% for the 2002 second quarter
and 11% for the 2002 first half due primarily to higher sales of human
pharmaceuticals. There was no foreign exchange impact on worldwide
pharmaceutical net revenue for the 2002 second quarter, however, for the 2002
first half, worldwide pharmaceutical net revenue increased 12%, excluding the
negative impact of foreign exchange.
15
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
Worldwide human pharmaceutical net revenue increased 13% for the 2002 second
quarter and 11% for the 2002 first half due primarily to higher sales of EFFEXOR
(as a result of higher volume caused by an increase in prescriptions and a
wholesalers' buy-in before a price increase), PROTONIX and CORDARONE offset, in
part, by lower sales of PREVNAR (due primarily to constraints on finished
product availability) and generic products (discontinuance of certain oral
generics). Refer to the "Product Supply" section herein for further discussion
of PREVNAR product availability issues. There was no foreign exchange impact on
worldwide human pharmaceutical net revenue for the 2002 second quarter, however,
worldwide human pharmaceutical net revenue increased 12% for the 2002 first
half, excluding the negative impact of foreign exchange.
The following table sets forth the significant human pharmaceutical net revenue
product fluctuations for the three and six months ended June 30, 2002 compared
to the same periods in the prior year:
Three Months Six Months
Ended June 30, Ended June 30,
----------------------- -----------------------
($ in millions) $ Increase % Increase $ Increase % Increase
Products (Decrease) (Decrease) (Decrease) (Decrease)
- --------------------------- ---------- ---------- ---------- ----------
EFFEXOR $249.2 70% $359.8 54%
PROTONIX 60.1 45% 147.0 50%
CORDARONE 15.3 25% 95.0 89%
PREVNAR (46.6) (24)% (106.0) (26)%
Oral generics (45.2) (100)% (93.3) (100)%
Other 81.0 5% 181.9 5%
------ ------ ------ ------
Total human pharmaceuticals $313.8 13% $584.4 11%
====== ====== ====== ======
Worldwide animal health product net revenue increased 1% for the 2002 second
quarter and was flat for the 2002 first half as domestic sales of the West Nile
Virus vaccine (introduced in the 2001 third quarter) were offset by decreased
sales of ProHeart 6.
Consumer Healthcare
- -------------------
Worldwide consumer healthcare net revenue increased 1% for the 2002 second
quarter and decreased 4% for the 2002 first half. The increase for the 2002
second quarter was due primarily to higher sales of the CENTRUM product line and
various other products offset, in part, by lower sales of ADVIL and
cough/cold/allergy products. The decrease for the 2002 first half was due
primarily to lower sales of cough/cold/allergy products, CALTRATE and ADVIL
offset, in part, by higher sales of the CENTRUM product line. There was no
foreign exchange impact on worldwide consumer healthcare net revenue for either
the 2002 second quarter or first half.
16
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
The following table sets forth the significant consumer healthcare net revenue
product fluctuations for the three and six months ended June 30, 2002 compared
to the same periods in the prior year:
Three Months Six Months
Ended June 30, Ended June 30,
----------------------- -----------------------
($ in millions) $ Increase % Increase $ Increase % Increase
Products (Decrease) (Decrease) (Decrease) (Decrease)
- --------------------------- ---------- ---------- ---------- ----------
CENTRUM $5.6 4% $17.1 7%
ADVIL (7.9) (7)% (4.0) (2)%
CALTRATE (0.6) (2)% (6.7) (10)%
Cough/cold/allergy products (6.3) (9)% (42.1) (23)%
Other 12.9 9% (4.1) (1)%
---- ---- ------ -----
Total consumer healthcare $3.7 1% ($39.8) (4)%
==== ==== ====== =====
The following table sets forth the percentage changes in worldwide net revenue
by operating segment compared to the prior year, including the effect volume,
price and foreign exchange had on these percentage changes:
% Increase (Decrease) % Increase (Decrease)
Three Months Ended June 30, 2002 Six Months Ended June 30, 2002
--------------------------------------- ---------------------------------------
Foreign Total Foreign Total
Volume Price Exchange Net Revenue Volume Price Exchange Net Revenue
------ ----- -------- ----------- ------ ----- -------- -----------
Pharmaceuticals
- -------------------
United States 10% 4% - 14% 8% 6% - 14%
International 6% 1% - 7% 6% 1% (2)% 5%
---- -- -- ---- ---- -- ---- ----
Total 9% 3% - 12% 8% 4% (1)% 11%
==== == == ==== ==== == ==== ====
Consumer Healthcare
- -------------------
United States (6)% 2% - (4)% (8)% 1% - (7)%
International 6% 3% 1% 10% 1% 2% (1)% 2%
---- -- -- ---- ---- -- ---- ----
Total (1)% 2% - 1% (5)% 1% - (4)%
==== == == ==== ==== == ==== ====
Total
- -------------------
United States 7% 4% - 11% 6% 5% - 11%
International 6% 1% 1% 8% 5% 1% (2)% 4%
---- -- -- ---- ---- -- ---- ----
Total 7% 3% - 10% 5% 4% (1)% 8%
==== == == ==== ==== == ==== ====
Cost of goods sold, as a percentage of Net revenue, increased
less than one percentage point to 25.3% for the 2002 second quarter compared
with 24.8% for the 2001 second quarter and decreased to 23.6% for the 2002 first
half compared to 24.1% for the 2001 first half. The increase in Cost of goods
sold, as a percentage of Net revenue, for the 2002 second quarter is
attributable to the costs of addressing various manufacturing issues as
described in the "Product Supply" section, herein. The decrease for the first
half was due primarily to an increase in sales volume on higher margin products
and the discontinuance of the lower margin oral generics business in the
pharmaceuticals segment, as well as an impact relating to increased alliance
revenue recorded in 2002 net revenue compared to 2001 net revenue. There are no
costs of
17
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
goods sold relating to alliance revenue, and therefore any net revenue
fluctuations impacted by alliance revenue also impact gross margins. The
decrease of Cost of goods sold, as a percentage of Net revenue, for the 2002
first half, was partially offset by the costs of addressing various
manufacturing issues experienced in the second quarter.
Selling, general and administrative expenses, as a percentage of Net revenue,
decreased to 37.4% for the 2002 second quarter and 36.1% for the 2002 first half
compared with 38.3% for the 2001 second quarter and 36.8% for the 2001 first
half (excluding the effect of goodwill amortization). The decrease was primarily
due to net revenue growth outpacing spending for various selling and marketing
programs.
Research and development expenses increased 10% for the 2002 second quarter and
8% for the 2002 first half due primarily to increased headcount and other
research operating expenses, including higher chemical and material costs,
clinical grant spending and cost sharing expenditures relating to pharmaceutical
collaborations offset, in part, by lower payments under licensing agreements.
Interest expense, net increased 12% for the 2002 second quarter and over 100% in
the 2002 first half due primarily to higher weighted average debt outstanding
and lower interest income, as compared with prior year levels. Weighted average
debt outstanding during the 2002 second quarter and first half was $10,375.3
million and $10,154.8 million, respectively compared with prior year levels of
$7,511.6 million and $5,720.8 million, respectively. The impact of higher debt
outstanding was partially offset by lower interest rates on outstanding
commercial paper.
Other income, net increased 94% for the 2002 second quarter and 39% for the 2002
first half due primarily to a class action settlement regarding price fixing by
certain vitamin suppliers and higher gains on sales of non-strategic assets.
The following table sets forth worldwide income before taxes by operating
segment together with the percentage changes from the comparable period in the
prior year:
Income Before Taxes (1)
---------------------------------------------------------------------
Three Months Six Months
Ended June 30, Ended June 30,
------------------------------ ----------------------------------
($ in millions)
Operating Segment 2002 2001 % Increase 2002 2001 % Increase
- ----------------------- ------ ------ ---------- -------- -------- ----------
Pharmaceuticals $736.6 $601.2 23% $1,809.8 $1,516.7 19%
Consumer Healthcare (2) 143.4 112.1 28% 302.9 236.1 28%
------ ------ ---------- -------- -------- ----------
880.0 713.3 23% 2,112.7 1,752.8 21%
Corporate (108.3) (81.4) 33% (218.8) (139.9) 56%
------ ------ ---------- -------- -------- ----------
Total $771.7 $631.9 22% $1,893.9 $1,612.9 17%
====== ====== ========== ======== ======== ==========
(1) In accordance with new authoritative accounting guidance, adopted as of
January 1, 2002, the Company has ceased amortizing goodwill. The 2001
second quarter goodwill amortization was as follows: Pharmaceuticals -
$34.1 and Consumer Healthcare - $5.9. The 2001 first half goodwill
amortization was as follows: Pharmaceuticals - $68.7 and Consumer
Healthcare - $11.9. Excluding goodwill amortization from the 2001
18
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
second quarter and first half results, Pharmaceuticals and Consumer
Healthcare income before taxes increased 16% and 22%, respectively, for the
2002 second quarter and 14% and 22%, respectively, for the 2002 first half.
(2) Consumer Healthcare includes gains of $40.3 and $73.9 in the 2002 second
quarter and first half, respectively, related to a class action settlement
regarding price fixing by certain vitamin suppliers. Excluding the
settlement gains from the 2002 second quarter and first half results,
Consumer Healthcare income before taxes decreased 8% and 3%, respectively.
Worldwide pharmaceutical income before taxes increased 16% for the 2002 second
quarter and 14% for the 2002 first half (excluding goodwill amortization from
the 2001 second quarter and first half) due primarily to increased worldwide
sales of human pharmaceuticals and lower selling, general and administrative
expenses as a percentage of net revenue offset, in part, by higher research and
development expenses and lower other income, net (primarily lower gains on sales
of non-strategic assets).
Worldwide consumer healthcare income before taxes increased 22% for the 2002
second quarter and first half (excluding goodwill amortization from the 2001
second quarter and first half) while consumer healthcare net sales increased 1%
for the 2002 second quarter and decreased 4% for the 2002 first half. This
difference is primarily attributable to the class action settlement gain
recorded in the 2002 first half relating to price fixing by certain vitamin
suppliers, higher gains on asset sales and lower selling, general and
administrative expenses as a percentage of net sales.
Corporate expenses, net, increased 33% for the 2002 second quarter and 56% for
the 2002 first half due primarily to higher interest expense, resulting from
higher weighted average debt outstanding and lower interest income, and higher
general and administrative expenses.
The effective tax rate decreased to 22.3% for both the 2002 second quarter and
first half compared with 23.3% and 24.0% for the 2001 second quarter and first
half (excluding the effect of goodwill amortization). The tax rate reduction
occurring in the 2002 second quarter and first half was primarily due to an
increased benefit from products manufactured in lower taxed jurisdictions.
Consolidated Net Income and Diluted Earnings Per Share Results
- --------------------------------------------------------------
Net income and diluted earnings per share for the 2002 second quarter increased
to $599.9 million and $0.45 compared with $477.0 million and $0.36 in the prior
year, increases of 26% and 25%, respectively. On January 1, 2002, the Company
adopted SFAS No. 142, which eliminated the amortization of goodwill. Excluding
the after-tax goodwill amortization of $38.2 million and $0.03 per share-diluted
from the 2001 second quarter results, net income and diluted earnings per share
for the 2002 second quarter increased 16% and 15%, respectively. The increases
in net income and diluted earnings per share for the 2002 second quarter were
greater than the growth rate in net revenue due primarily to lower selling,
general and administrative expenses as a percentage of net revenue, higher other
income, net and a lower effective tax rate as a result of products manufactured
in lower taxed jurisdictions.
19
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
Net income and diluted earnings per share for the 2002 first half increased to
$1,471.8 million and $1.10 compared with $1,210.6 million and $0.91 in the prior
year, increases of 22% and 21%, respectively. Excluding the after-tax goodwill
amortization of $76.9 million and $0.06 per share-diluted from the 2001 first
half results, net income and diluted earnings per share for the 2002 second
quarter increased 14% and 13%, respectively. The same items that impacted the
2002 second quarter difference in growth rates between net revenue and net
income contributed to the differential for the 2002 first half. In addition,
2002 first half growth rates were impacted by higher interest expense.
Liquidity, Financial Condition and Capital Resources
- ----------------------------------------------------
The Company used net cash for operating activities totaling $320.4 million
during the 2002 first half. Driving the cash outflows were payments of $895.9
million relating to the diet drug litigation (see Note 3 to the Consolidated
Condensed Financial Statements), payments of $415.0 million to a security fund
as collateral for the Company's financial obligations under the diet drug
settlement, payments made on outstanding payables and accrued expenses totaling
$90.4 million and an increase in inventories of $289.3 million due primarily to
production planning. These outflows more than offset earnings generated during
the period.
The Company used $787.7 million of cash during the 2002 first half for
investments in property, plant and equipment. The capital expenditures made
during the 2002 first half were consistent with the Company's commitment to
expand existing manufacturing and research and development facilities worldwide,
and build new biotechnology facilities. The Company received investment proceeds
through the sales and maturities of marketable securities and the sales of
assets totaling $1,706.7 million. Included in the proceeds from sales of assets
in 2002 is approximately $298.6 million relating to the sale of the Company's
retrofitted Rhode Island facility to Immunex.
The Company obtained cash for financing activities through $1,377.2 million of
net proceeds from debt and $186.7 million of cash provided by stock option
exercises partially offset by dividend payments of $609.4 million and purchases
of treasury stock of $113.9 million.
At June 30, 2002, the Company had outstanding $10,833.6 million in total debt.
The Company's total debt consisted of commercial paper of $6,138.4 million, and
notes payable and other debt of $4,695.2 million. Current debt at June 30, 2002,
classified as Loans payable, consisted of:
o $1,000.0 million of commercial paper supported by the $1,000.0 million
credit facility that terminates in less than one year,
o $2,138.4 million of commercial paper that is in excess of the $4,000.0
million credit facilities and is supported by $3,176.2 million of cash and
cash equivalents and marketable securities, and
o $267.4 million of notes payable and other debt that is due within one year.
The portion of commercial paper outstanding at June 30, 2002 supported by the
$3,000.0 million, 364-day credit facility was classified as Long-term debt since
the Company intends, and has the
20
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
ability, to refinance these obligations through the issuance of additional
commercial paper or through the use of its $3,000.0 million credit facility.
Following the termination of its $1,000.0 million credit facility on July 31,
2002, the Company obtained a 364-day $2,000.0 million credit facility, which
contemplates a potential increase to $3,000.0 million if the Company so requests
and lenders agree to participate. The facility will be reduced to 66.67% of its
committed amount on December 31, 2002 and to 33.34% of its committed amount on
May 8, 2003. In addition, in the event the Company enters into certain
alternative financings or asset sales, the committed amount will be reduced by
the amount of proceeds received therefrom.
Management believes that this new facility, together with the Company's existing
$3,000.0 million credit facility and significant cash balances (including the
$1,005.0 million received in July from the acquisition of Immunex by Amgen),
should provide for adequate liquidity needs of the Company for the foreseeable
future. Although the Company offers its commercial paper in a liquid market
commensurate with it short-term credit ratings from Moody's (P2), S&P (A1) and
Fitch (A1), the credit markets have been increasingly volatile and sensitive to
unfavorable developments. Accordingly, and in light of the relatively large size
of the Company's commercial paper program, the Company is currently evaluating
financing alternatives to support longer term liquidity requirements.
Management remains confident that cash flows from operating activities and
existing and prospective financing resources will be adequate to fund the
Company's operations, pay opt out settlement payments and fund the nationwide,
class action settlement relating to the REDUX and PONDIMIN diet drug litigation,
pay dividends, maintain the ongoing programs of capital expenditures, and repay
both the principal and interest on its outstanding obligations, without
requiring the disposition of any significant strategic core assets or
businesses.
Quantitative and Qualitative Disclosures About Market Risk
- ----------------------------------------------------------
The market risk disclosures appearing on pages 64 and 65 of the Company's 2001
Annual Report as incorporated by reference on Form 10-K have not materially
changed from December 31, 2001.
At June 30, 2002, the fair values of the Company's financial instruments were as
follows:
($ in millions) Notional/
Description Contract Amount Carrying Value Fair Value
- --------------------- --------------- -------------- ----------
Forward contracts (1) $629.9 $8.1 $8.1
Option contracts (1) 650.5 (20.9) (20.9)
Interest rate swaps 1,500.0 67.4 67.4
Outstanding debt (2) 10,770.8 10,833.6 11,015.3
(1) If the value of the U.S. dollar were to increase or decrease by 10%, in
relation to all hedged foreign currencies, the net receivable on the forward
and option contracts would decrease or increase by approximately $79.4.
21
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
(2) If the interest rates were to increase or decrease by one percentage point,
the fair value of the outstanding debt would increase or decrease by
approximately $205.4.
The estimated fair values approximate amounts at which these financial
instruments could be exchanged in a current transaction between willing parties.
Therefore, fair values are based on estimates using present value and other
valuation techniques that are significantly affected by the assumptions used
concerning the amount and timing of estimated future cash flows and discount
rates that reflect varying degrees of risk. Specifically, the fair value of
outstanding debt instruments reflects a current yield valuation based on
observed market prices as of June 30, 2002; the fair value of interest rate
swaps and forward contracts reflects the present value of the future potential
gain or (loss) if settlement were to take place on June 30, 2002; and the fair
value of option contracts reflects the present value of future cash flows if the
contracts were settled on June 30, 2002.
Cautionary Statements for Forward-Looking Information and Factors that May
- --------------------------------------------------------------------------
Affect Future Results
- ---------------------
This Form 10-Q, including management's discussion and analysis set forth above,
contains certain forward-looking statements, including, among other things,
statements regarding the Company's results of operations, competition,
liquidity, financial condition and capital resources, PREVNAR sales,
PREMPRO/PREMARIN, product supply, foreign currency and interest rate risk, the
nationwide, class action settlement relating to REDUX and PONDIMIN, and
additional litigation charges related to REDUX and PONDIMIN including those for
opt outs. These forward-looking statements are based on current expectations of
future events that involve risks and uncertainties including, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development, manufacturing, commercialization, economic
conditions including interest and currency exchange rate fluctuations, access to
capital markets, the impact of competitive or generic products, product
liability and other types of lawsuits, the impact of legislative and regulatory
compliance and obtaining approvals, and patents. From time to time, we also may
provide oral or written forward-looking statements in other materials we release
to the public. However, the Company assumes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future
events or otherwise. Certain factors which could cause the Company's actual
results to differ materially from expected and historical results are discussed
herein and others have been identified by the Company in Exhibit 99 to the
Company's 2001 Annual Report on Form 10-K, which exhibit is incorporated herein
by reference.
Prempro / Premarin - HRT Studies
Two subsets of the WHI enrolled a total of 27,000 predominantly healthy
postmenopausal women to assess the risks and benefits of either long-term
estrogen replacement therapy (ERT) or long-term hormone replacement therapy
(HRT). The primary endpoint of the WHI study was coronary heart disease, with
invasive breast cancer as the primary adverse outcome studied. In the HRT subset
of the WHI, involving women who received hormone replacement therapy for an
average of 5.2 years using a combination of conjugated estrogens and
medroxyprogesterone
22
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
acetate (PREMPRO), increased rates of cardiovascular disease and breast cancer
were observed. This subset was stopped early because, according to the
predefined stopping rule, the increased risk of breast cancer and cardiovascular
events exceeded the specified long-term benefits. The study observed an
increased incidence of cardiovascular disease and, over time, breast cancer
among women on HRT compared to those on placebo. The study also observed a
reduction in the incidence of hip, vertebral and other osteoporotic fractures
and of colon cancer among women on HRT compared to those on placebo. The study
did not evaluate the use of HRT for the treatment of menopausal symptoms, the
main use of the product. These findings provide additional information about the
risks of breast cancer and cardiovascular disease which are potential adverse
events identified in the existing labeling for the Company's HRT products. A
great deal of media attention has been focused on this subject.
As a result, sales of PREMPRO and other PREMARIN family products are likely to
be adversely affected. Although the Company is currently monitoring the
situation, including prescription trends for the PREMARIN family of products and
other relevant information, it is not yet able to specifically quantify the
impact on future sales or operating results. The study subset which was
terminated focused on the long-term use of PREMPRO and did not involve PREMARIN
(ERT). PREMPRO sales (including PREMPHASE) for the three and six months ended
June 30, 2002 represented approximately 5% of consolidated net revenue for both
periods. Set forth below are individual product operating results for
PREMPRO/PREMPHASE and PREMARIN for both the three and six months ended June 30,
2002 and 2001.
Prempro/Premphase
-------------------------------------------
Three Months Six Months
Ended June 30, Ended June 30,
----------------- -----------------
($ in millions) 2002 2001 2002 2001
- --------------- ------ ------ ------ ------
Net revenue $171.5 $178.8 $387.6 $435.9
Gross profit 147.2 153.9 332.9 377.3
Premarin
-------------------------------------------
Three Months Six Months
Ended June 30, Ended June 30,
----------------- -----------------
($ in millions) 2002 2001 2002 2001
- --------------- ------ ------ ------ ------
Net revenue $273.9 $249.4 $733.3 $624.1
Gross profit 247.0 226.6 676.1 574.2
Competition
The Company operates in the highly competitive pharmaceutical and consumer
health care industries. PREMARIN, the Company's principal conjugated estrogens
product manufactured from pregnant mare's urine, and related products PREMPRO
and PREMPHASE (which are single tablet combinations of the conjugated estrogens
in PREMARIN and the progestin medroxyprogesterone acetate), are the leaders in
their categories and contribute significantly to net revenue and results of
operations. PREMARIN's natural composition is not subject to patent protection
(although PREMPRO has patent protection). The principal uses of PREMARIN,
PREMPRO and PREMPHASE are to manage the symptoms of menopause and to prevent
23
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
osteoporosis, a condition involving a loss of bone mass in postmenopausal women.
Estrogen-containing products manufactured by other companies have been marketed
for many years for the treatment of menopausal symptoms, and several of these
products also have an approved indication for the prevention of osteoporosis.
During the past several years, other manufacturers have introduced products for
the treatment and/or prevention of osteoporosis. New products containing
different estrogens than those found in PREMPRO and PREMPHASE and having many
forms of the same indications have also been introduced. Some companies have
attempted to obtain approval for generic versions of PREMARIN. These products,
if approved, would be routinely substitutable for PREMARIN and related products
under many state laws and third-party insurance payer plans. In May 1997, the
FDA announced that it would not approve certain synthetic estrogen products as
generic equivalents of PREMARIN given known compositional differences between
the active ingredient of these products and PREMARIN. Although the FDA has not
approved any generic equivalent to PREMARIN to date, PREMARIN will continue to
be subject to competition from existing and new competing estrogen and other
products for its approved indications and may be subject to generic competition
from either synthetic or natural conjugated estrogens products in the future. At
least one other company has announced that it is in the process of developing a
generic version of PREMARIN from the same natural source, and the Company
currently cannot predict the timing or outcome of these or any other efforts.
The marketing exclusivity for CORDARONE I.V. expired on August 3, 2002. The
Company submitted an application to the FDA for a six month pediatric extension
of the marketing exclusivity. The Company cannot predict whether its application
will be granted or when any generic competition will be approved. CORDARONE I.V.
had sales of $192 million during the first six months of 2002.
Product Supply
Although the market demand for ENBREL is increasing, the sales growth currently
is constrained by limits on the existing source of supply. This is expected to
continue until the retrofitting of a Rhode Island facility owned by Amgen is
completed and approved, which is currently anticipated to occur in the first
quarter of 2003, although there is no assurance that this estimate will prove
accurate. If the market demand continues to grow, there may be further supply
constraints even after the Rhode Island facility begins producing ENBREL. In
April 2002, Immunex (prior to being acquired by Amgen) announced a manufacturing
agreement with Genentech, Inc. to produce ENBREL beginning in 2004, subject to
FDA approval. The current plan for the longer term includes an additional
manufacturing facility, which is being constructed by the Company in Ireland and
is expected to be completed during 2005.
The Company has been experiencing inconsistent results on dissolution testing of
certain dosage forms of PREMARIN and is working with the FDA to resolve this
issue. Until this issue is resolved, supply shortages of one or more dosage
strengths may occur. Although these shortages may adversely affect PREMARIN
sales in one or more accounting periods, the Company believes that, as a result
of current inventory levels and the Company's enhanced process controls, testing
protocols and the ongoing formulation improvement project, overall PREMARIN
family sales will not be significantly impacted by the dissolution issues (see
also Prempro / Premarin - HRT Studies).
24
Management's Discussion and Analysis of Financial Condition
and Results of Operations
Three Months and Six Months Ended June 30, 2002
Sales of PREVNAR continue to be affected by manufacturing-related constraints on
product availability. The Company is in the process of implementing
manufacturing improvements and allocating additional personnel and equipment to
increase production of PREVNAR. The Company's efforts are not expected to
significantly increase supply until 2003 and, as a result, 2002 PREVNAR sales
are not expected to significantly exceed prior year levels. However, the
manufacturing processes for this product are very complex and there can be no
assurance that manufacturing-related difficulties will not result in further
reductions in 2002 sales.
Litigation and Contingent Liabilities
The Company is involved in various legal proceedings, including product
liability and environmental matters that arise from time to time in the ordinary
course of business, the most significant of which are described in the Company's
Annual Report on Form 10-K for the year ended December 31, 2001, Quarterly
Report on Form 10-Q for the quarter ended March 31, 2002 and this Quarterly
Report on Form 10-Q. These include allegations of injuries caused by drugs and
other over-the-counter products, including REDUX, PONDIMIN, DIMETAPP,
ROBITUSSIN, DURACT and PREMPRO. In addition, the Company has responsibility for
environmental, safety and cleanup obligations under various local, state and
federal laws, including the Comprehensive Environmental Response, Compensation
and Liability Act, commonly known as Superfund.
The estimated costs that the Company expects to pay in these cases are accrued
when the liability is considered probable and the amount can be reasonably
estimated. In many cases, future environmental-related expenditures cannot be
quantified with a reasonable degree of accuracy. As investigations and cleanups
proceed, environmental-related liabilities are reviewed and adjusted as
additional information becomes available. In addition, the Company is
self-insured against ordinary product liability risks and has liability
coverage, in excess of certain limits and subject to certain policy ceilings,
from various insurance carriers. It is the opinion of the Company that any
potential liability that might exceed amounts already accrued will not have a
material adverse effect on the Company's financial position but could be
material to the results of operations or cash flows in any one accounting
period.
25
Part II - Other Information
---------------------------
Item 1. Legal Proceedings
-----------------
The Company and its subsidiaries are parties to numerous lawsuits and
claims arising out of the conduct of its business, including product
liability and other tort claims, the most significant of which are
described below and in the Company's Annual Report on Form 10-K for
the year ended December 31, 2001 and Quarterly Report on Form 10-Q for
the quarter ended March 31, 2002.
On July 9, 2002, findings from the WHI study evaluating hormone
replacement therapy were released and the subset of the study
involving use of the Company's PREMPRO product was stopped early.
Since that announcement, the Company has been named in six putative
class action lawsuits. Four of the six putative class actions seek to
represent a nationwide class of all women who have ever purchased or
ingested PREMPRO and seek, on behalf of the class, purchase price
refunds, personal injury damage, medical monitoring expenses and an
order requiring the Company to inform the public of the reported risks
of PREMPRO. Bloch, et al. v. Wyeth, No. 02CV4984 U.S.D.C., E.D.Pa.;
Geller, et al. v. Wyeth, No. 02CV4718, U.S.D.C., E.D.Pa.; Lewers, et
al. v. Wyeth, No.02C4970, U.S.D.C., N.D. Ill.; Goldstein, et al. v.
Wyeth, No. CA02-8831AB, Cir. Ct., Palm Beach Cty., FL. The other two
putative class actions each seek to represent a class of Pennsylvania
women who have ingested the drug and seek purchase price refunds and
medical monitoring expenses on behalf of the class. Gallo, et al. v.
Wyeth, No. 002857, Ct. Comm. Pleas, Philadelphia Cty., PA; Finnigan,
et al. v. Wyeth, Inc., et al., No. 000007, Ct. Comm. Pleas,
Philadelphia Cty., PA. Following the filing of the Company's motion to
dismiss the Bloch class action for failure to state a claim,
plaintiffs have voluntarily dismissed the case. The Company expects
that additional PREMPRO cases may be filed in the future. At this
time, the Company is unable to determine any possible range of loss
relating to the PREMPRO litigation and has not established any reserve
with respect to any such litigation, but expects to incur costs in
connection with the defense of the PREMPRO litigation. The Company
believes it has meritorious defenses against these claims and intends
to vigorously defend any PREMPRO litigation.
In the litigation involving those formulations of the Company's
DIMETAPP and ROBITUSSIN cough/cold products that contained the
ingredient phenylpropanolamine (PPA), United States District Judge
Barbara Jacobs Rothstein, who is supervising the federal multidistrict
PPA litigation, has denied class certification in the putative federal
class actions seeking damages for alleged personal injuries. In re
Phenylpropanolamine (PPA) Products Liability Litigation, M.D.L. 1407,
U.S.D.C., W.D. Wash. The Company is currently named as a defendant in
412 PPA lawsuits involving 913 named plaintiffs. Of these lawsuits,
401 are individual product liability suits and eleven are purported
class actions. Of the class action suits, eight allege economic
injury caused by alleged misrepresentations regarding the risks
involved with products containing PPA and three allege personal
injury. The Company expects that additional PPA cases may be filed in
the future against it and the other companies that marketed
PPA-containing products.
In the litigation involving allegations that the cumulative effect of
thimerosal, a preservative used in certain vaccines manufactured and
distributed by the Company as well as by other vaccine manufacturers,
causes severe neurological damage, including
26
autism in children, three additional class actions have been filed.
Bothwell, et al. v. Abbott, et al., No. BC270631, Super. Ct., Los
Angeles Cty., CA is a putative nationwide class action seeking
compensatory and punitive damages and injunctive relief. Wax, et al.
v. Abbott, et al., No. CV 02 2018, U.S.D.C., E.D.N.Y., is also a
putative nationwide class action and seeks medical monitoring, a
court-supervised research program and compensatory and punitive
damages. Daigle, et al. v. Aventis Pasteur, Inc., et al., No.
02-2131F, Super. Cty., Suffolk Cty., MA is statewide class for medical
monitoring and injunctive relief. The Company has now been named as a
defendant in 88 lawsuits involving 402 named plaintiffs. Of these
lawsuits, 75 are individual product liability suits and thirteen are
purported class actions. The Company expects that additional
thimerosal cases may be filed in the future against it and the other
companies that marketed thimerosal-containing products.
In the litigation involving DURACT, the Company's non-narcotic
analgesic pain reliever which was voluntarily withdrawn from the
market, there are currently a total of 24 individual lawsuits pending
involving 685 former DURACT users alleging various injuries, from
gastrointestinal upset and distress to liver transplant and death. As
previously reported, two putative class actions also remain pending,
although no certified class currently exists.
The Company is unable at the present time to estimate a range of
potential exposure, if any, with respect to the PREMPRO, PPA,
thimerosal and DURACT litigations.
The Company has been named as a defendant in an additional lawsuit
alleging Medicare fraud arising out of the alleged manipulation of the
Average Wholesale Price (AWP) of Medicare Part B Covered Drugs. The
AWP sets the reimbursement amount of the Medicare Part B Covered Drugs
and also is typically used in calculating Medicare rebates. Rice, et
al. v. Abbott Laboratories, Inc., et al., No. 2002057720, Super. Ct.,
Alameda Cty., CA, is a putative class action on behalf of California
patients and third-party payers who allegedly have been injured by the
defendants' alleged manipulation of the AWPs for their pharmaceutical
products. The Complaint names 37 other pharmaceutical manufacturers
and 50 unidentified companies as co-defendants. It seeks injunctive
relief and compensatory and punitive damages under Section 17200 of
the California Business and Professions Code, which is the state's
unfair and deceptive trade practices statute.
In the brand name prescription drugs litigation, the Company settled
the following cases: Paradise Drugs, Inc. v. Abbott Labs., CV 793852
(Ca. Super. Ct., Santa Clara Cty.); Paradise Drugs, Inc. v. Abbott
Labs., 95 C 1001 (N.D. Ill.) (originally filed in N.D. Ca. as
94-20819); Bob's Pharmacy, Inc. v. Abbott Labs., 95C 2617 (N.D. Ill.)
(originally filed in N.D. Ca. as C95-20105); G&B Pharmacy Group, Inc.
v. Abbott Labs., 95 C 1088 (N.D. Ill.); Robar One, Inc. v. Abbott
Labs., 95 C 1083 (N.D. Ill.); Haven Pharmacy, Inc. v. Abbott Labs., 95
C 0663 (N.D. Ill.); and Lawrence Adams v. Abbott Labs., 95 C 2805
(N.D. Ill.) (originally filed in E.D. Ark. as LR-C-95-153). The
amounts of these settlements are confidential and are not material to
the Company, individually or in the aggregate.
The Company's pending settlement of the administrative complaint of
the Federal Trade Commission (FTC) in In Re: Schering-Plough
Corporation, et al., Docket No. 9297, described in the Company's
Annual Report on Form 10-K has become final.
27
Accordingly, the FTC entered a final consent order pursuant to which
the Company generally agreed not to be a party to a settlement in a
patent infringement matter in which an NDA holder agrees to provide
anything of value to an alleged infringer and the infringer agrees to
refrain from selling the drug for any period of time. However, the
Company is permitted under the order to enter such agreements in
certain circumstances when the agreement has been approved by a court
or the FTC. The settlement is not an admission of liability and was
entered into to avoid the costs and risks of litigation.
The Florida attorney general's office has initiated an inquiry into
whether the Company's 1998 settlement with Schering-Plough Corp. of a
patent dispute relating to a potassium chloride product violates
Florida antitrust laws. The Company is providing documents and
information sought by the attorney general's office.
The Company intends to continue to defend all of the foregoing
litigation vigorously.
In the opinion of the Company, although the outcome of any legal
proceedings cannot be predicted with certainty, the ultimate liability
of the Company in connection with its legal proceedings will not have
a material adverse effect on the Company's financial position but
could be material to the results of operations or cash flows in any
one accounting period.
28
Item 4. Submission of Matters to a Vote of Security-Holders
---------------------------------------------------
(a) The matters described under item 4(c) below were submitted to a
vote of security-holders, through the solicitation of proxies
pursuant to Section 14 under the Securities Exchange Act of 1934,
as amended, at the Annual Meeting of Stockholders held on April
25, 2002 (the "Annual Meeting").
(b) Not applicable.
(c) The following describes the matters voted upon at the Annual
Meeting and sets forth the number of votes cast for, against or
withheld and the number of abstentions as to each such matter
(except as provided below, there were no broker non-votes):
(i) Election of directors:
Nominee For Withheld
------- --- --------
Clifford L. Alexander, Jr. 1,060,596,130 9,323,046
Frank A. Bennack, Jr. 1,060,809,427 9,109,749
Richard L. Carrion 1,060,680,744 9,238,432
Robert Essner 1,061,457,884 8,461,292
John D. Feerick 1,060,538,649 9,380,527
John P. Mascotte 1,060,990,539 8,928,637
Mary Lake Polan, M.D., Ph.D 1,061,134,813 8,784,363
Ivan G. Seidenberg 1,060,724,594 9,194,582
Walter V. Shipley 1,060,796,909 9,122,267
John R. Stafford 1,060,688,467 9,230,709
John R. Torell III 1,061,151,165 8,768,011
(ii) Ratification of the appointment of PricewaterhouseCoopers
LLP as principal independent public accountants for 2002:
For Against Abstain
--- ------- -------
1,052,541,796 18,258,818 6,966,293
(iii)Adoption of the 2002 Stock Incentive Plan:
For Against Abstain
--- ------- -------
978,880,961 89,094,336 9,791,610
(iv) Adoption of the Executive Incentive Plan:
For Against Abstain
--- ------- -------
966,515,144 100,694,482 10,557,281
(v) Requirement Regarding Stockholder approval of Poison Pills:
For Against Abstain
--- ------- -------
608,913,844 298,371,500 13,463,308
There were 157,018,255 broker non-votes with reference to
this item.
29
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
(a) Exhibits
--------
Exhibit No. Description
----------- -----------
(2.1) Amended and Restated Agreement and Plan of
Merger, dated as of December 16, 2001, by and
among Amgen, AMS Acquisition Inc. and Immunex
(filed as Annex A to Amendment No. 1 to Amgen's
Registration Statement on Form S-4 (File No.
333-81832) on March 22, 2002 and incorporated
herein by reference).
(2.2) First Amendment to Amended and Restated Agreement
and Plan of Merger dated as of July 15, 2002, by
and among Amgen, AMS Acquisition Inc. and Immunex
(filed as Exhibit 2.2 to Post-Effective Amendment
No. 1 to Amgen's Registration Statement on Form
S-4 (File No. 333-81832) on July 15, 2002 and
incorporated herein by reference).
(10.1) Stockholders' Rights Agreement, dated as of
December 16, 2001, by and among Amgen, the
Company, MDP Holdings, Inc. and Lederle
Parenterals, Inc. (filed as Annex C to Amendment
No. 1 to Amgen's Registration Statement on Form
S-4 (File No. 333-81832) on March 22, 2002 and
incorporated herein by reference).
(10.2) Shareholder Voting Agreement, dated as of
December 16, 2001, among Amgen Inc., Wyeth
(formerly American Home Products Corporation),
MDP Holdings, Inc. and Lederle Parenterals, Inc.
(incorporated by reference to Exhibit 2.2 of
Immunex's Current Report on Form 8-K filed
December 17, 2001).
(10.3) 2002 Stock Incentive Plan (incorporated by reference to
Appendix C of the Company's definitive Proxy Statement
filed March 20, 2002).
(10.4) Executive Incentive Plan (incorporated by reference to
Appendix D of the Company's definitive Proxy Statement
filed March 20, 2002).
(10.5) Executive Retirement Plan, as amended to date.
(10.6) Supplemental Executive Retirement Plan, as
amended to date.
30
(10.7) Credit Agreement among Wyeth, the Lenders Parties
Thereto, J.P. Morgan Securities Inc. and Salomon
Smith Barney Inc. (as co-lead arrangers and joint
book managers), Citibank, N.A. (as syndication
agent) and J.P. Morgan Chase Bank (as
administration agent), dated as of August 7, 2002.
(12) Computation of Ratio of Earnings to Fixed Charges.
(b) Reports on Form 8-K
-------------------
There were no Current Reports on Form 8-K filed by the Company
during the 2002 second quarter. However, the Company filed the
following subsequent to June 30, 2002:
o On July 29, 2002, a Current Report on Form 8-K (including
disclosure under Items 2 and 7) relating to the sale of
Immunex shares in the acquisition of Immunex by Amgen.
31
Signature
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Wyeth
-----
(Registrant)
By /s/ Paul J. Jones
-----------------
Paul J. Jones
Vice President and Comptroller
(Duly Authorized Signatory
and Chief Accounting Officer)
Date: August 8, 2002
32
Exhibit Index
-------------
Exhibit No. Description
----------- -----------
(10.5) Executive Retirement Plan, as amended to date.
(10.6) Supplemental Executive Retirement Plan, as amended to date.
(10.7) Credit Agreement among Wyeth, the Lenders Parties Thereto, J.P.
Morgan Securities Inc. and Salomon Smith Barney Inc. (as co-lead
arrangers and joint book managers), Citibank, N.A. (as
syndication agent) and J.P. Morgan Chase Bank (as administration
agent), dated as of August 7, 2002.
(12) Computation of Ratio of Earnings to Fixed Charges.
EX-1